Crovalimab clinical trials
How each study uses Crovalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 20 Jun 2024 · PIASKY · BLA 761388 (FDA, Drugs@FDA)
- European Union
- 22 Aug 2024 · Piasky · EMEA/H/C/006061 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Crovalimab
- 10
Studies by the year they started
10 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Crovalimab, phase 3 first.
Studies
Open first, then newest update. How each study uses Crovalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement InhibitionActive, not recruitingPhase 3Hoffmann-La RocheNCT04654468Written as Crovalimab
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Active, not recruitingPhase 3Hoffmann-La RocheNCT04861259Written as Crovalimab
- A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement InhibitorsActive, not recruitingPhase 3Hoffmann-La RocheNCT04434092Written as Crovalimab
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement InhibitorsActive, not recruitingPhase 3Hoffmann-La RocheNCT04432584Written as Crovalimab
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Active, not recruitingPhase 3Hoffmann-La RocheNCT04958265Written as Crovalimab
- Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal HemoglobinuriaCompletedPhase 1/2Hoffmann-La RocheNCT03157635Written as Crovalimab
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)CompletedPhase 2Hoffmann-La RocheNCT05075824Written as Crovalimab
- A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)WithdrawnPhase 2Hoffmann-La RocheNCT07172022Written as Crovalimab
- A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).CompletedPhase 1Hoffmann-La RocheNCT04912869Written as Crovalimab
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)WithdrawnPhase 3Hoffmann-La RocheNCT05494619Written as Crovalimab
What changed recently
From the registry's own updates since Oct 15, 2026.
Codes
What other systems call Crovalimab · ClinicalTrials.gg INT002135
- MeSH (NLM) C000731754CrovalimabOne source NLM
- UNII (FDA) H9KH1GP3UUCROVALIMABConfirmed FDA, NLM
- NCI Thesaurus C169867CrovalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731754 | Crovalimab | One source NLM |
| UNII (FDA) | H9KH1GP3UU | CROVALIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C169867 | Crovalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.